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One of the most important factors in achieving a good
outcome is treatment adherence. Poor adherence to anti-
retroviral therapy (ART) leads to less viral suppression,
permanent treatment resistance and increased costs.
There are multiple causes of poor adherence: regimen
complexity, side effects etc.
Aim: to analyze ART adherence, risk factors for poor
adherence and their impact on the outcome.
We performed a one year survey (from January to
December 2013) of HIV infected patients monitored in
the Third Department of the National Institute for
Infectious Diseases “Prof. Dr. Matei Balş”. The data
(number of days covered by ART) was collected from
patients’ files. We correlated the adherence with gender,
regimen rank and complexity. Statistical analysis was
made using EPI INFO 6.
We retrospectively analyzed 111 patients who came in
to our clinic monthly to pick-up their ART, 52 women
(46.84%) and 59 men (53.16%) with a mean age of 43.5
years old. The adherence to ART was: 23 (20.62%) –
100% adherence, 36 (32.43%) – more than 96.7% adher-
ence (less than 12 days without medication), 38
(34.23%) – 91.8% to 96.7% adherence (13-30 days with-
out medication), 10 (9%) – 83.6% to 91.8% adherence
(30-60 days without medication) and 4 (3.6%) with less
than 83.6% adherence (more than 60 days without
medication). The level of adherence was correlated with
therapeutic failure: for 100% adherence – two failures
(8.69%), for more than 96.7% adherence – no failure,
for more than 91.8% adherence – 4 failures (11.1%), for
more than 83.6% adherence – 2 failures (20%) and for
less than 80% adherence – 3 failures (75%). Adherence
below 91.8% was correlated with treatment failure: RR
5.65 (CI95% 1.99; 16.09, p=0.0007). We analyzed some
possible risk factors for poor adherence: gender, regimen
rank and complexity. Although 51.95% from the non-
adherence group were women, the adherence wasn’t
correlated with gender: RR 1.23 (CI95% 0.93; 1.62,
p=0.16). A regimen rank higher than 1 was correlated
with low adherence – 45.76% vs. 28.84% in the adher-
ence vs. non-adherence group: RR 1.5 (CI95% 0.95; 2.38,
p=0.07). The regimen containing protease inhibitors
wasn’t correlated with low adherence: 33.9% vs. 30.8%,
RR 1.08 (CI95% 0.71; 1.67, p=0.73).
We emphasize the impact of therapy adherence on the
outcome. A level of adherence below 91% was correlated
with therapeutic failure. ART adherence wasn’t correlated
with gender, PI regimen and rank regimen.
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